Travera is an early-stage oncology startup on a mission to help oncologists make faster, more confident treatment decisions. Its Rapid Therapy Guidance (RTG) test, developed with MIT technology, evaluates a broad range of FDA-approved therapies against a patient’s tumor cells to determine the optimal treatment, delivering results in just two days. The test provides personalized, actionable insights to guide oncologists in selecting the most effective therapy for each patient.
To support commercialization, Travera needed to quickly build an advisory board of practicing oncologists who could act as trusted voices with peers and patients. Rather than assembling a traditional “celebrity” advisory board, Travera sought advisors who could provide authentic clinical feedback and strengthen go-to-market efforts.
As an early-stage company without an established clinical network, Travera lacked the connections to identify and vet these practicing experts quickly and effectively.
Travera partnered with the MDisrupt Expert Network to accelerate advisory board development. Within one month, MDisrupt sourced a pool of pre-vetted oncology experts, conducted additional screening to ensure clinical and strategic alignment, and delivered a curated shortlist of advisors for immediate engagement.
Through this process, Travera was able to:
For early-stage diagnostics companies, establishing a credible clinical advisory board is often a major growth challenge. By leveraging MDisrupt’s expert network, Travera rapidly assembled a group of trusted practicing oncologists whose insights helped to shape strategy, strengthen market positioning, and accelerate the delivery of its groundbreaking cancer diagnostics platform.
